TICKERNERD
Menu
ARQTARQTHealthcare · Biotechnology

ARQT Stock Forecast: Arcutis Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$26
+1.39% on the day

The 8 Wall Street analysts covering Arcutis Biotherapeutics, Inc. hold a median 12-month price target of $37 — +41.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$3.3B
Ticker Nerd rank
89 / 100
Median analyst target
$37
Analysts covering
8
Total return, dividends reinvested
1W
+3.6%
1M
−2.3%
YTD
−9.8%
1Y
+63.9%
From 52W high
−16.1%
From 52W low
+71.0%
$15
$31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARQT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arcutis Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
89 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Quality
95
Revisions
91
Growth
79
Momentum
78
Volatility
74
Size
30
Accruals
27
Issuance
26

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (26): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARQT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARQT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26ARQTHigh $40Median $37Low $34

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $34Median $37High $40

The green dot is the last close — the median target sits +41.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Aug 2026GuggenheimMaintainsBuy$35 → $38
6 Aug 2026Morgan StanleyMaintainsOverweight$34 → $38
6 Aug 2026NeedhamMaintainsBuy$36 → $40
7 May 2026NeedhamReiteratesBuy$36
7 May 2026NeedhamReiteratesBuy—
2 Mar 2026MizuhoMaintainsOutperform—
27 Feb 2026GuggenheimMaintainsBuy—
26 Feb 2026HC Wainwright & Co.MaintainsBuy—
26 Feb 2026NeedhamMaintainsBuy—
26 Feb 2026TD CowenMaintainsBuy—
26 Jan 2026NeedhamMaintainsBuy—
28 Nov 2025MizuhoMaintainsOutperform—
30 Oct 2025Goldman SachsMaintainsNeutral—
28 Oct 2025NeedhamMaintainsBuy—
7 Aug 2025NeedhamMaintainsBuy—
25 July 2025Goldman SachsInitiatesNeutral—
23 May 2025NeedhamReiteratesBuy—
9 Apr 2025NeedhamReiteratesBuy—
3 Apr 2025GuggenheimReiteratesBuy—
3 Apr 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARQT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ARQT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+149.5%
Analysts raising
1
Analysts cutting
0
Fundamentals

Arcutis Biotherapeutics, Inc. (ARQT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
119.0×

Cheaper than 6% of US stocks

Price / sales
7.1×

Cheaper than 19% of US stocks

Price / book
14.9×

Cheaper than 7% of US stocks

EV / EBITDA
86.8×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
59.3%

Higher than 89% of US stocks

Earnings growth (YoY)
59.3%

Higher than 78% of US stocks

Gross margin
91.6%

Higher than 97% of US stocks

Operating margin
12.7%

Higher than 68% of US stocks

Net margin
6.1%

Higher than 63% of US stocks

Returns & dividend
Return on equity
15.9%

Higher than 76% of US stocks

Return on assets
5.1%

Higher than 77% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ARQT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARQTArcutis Biotherapeutics, Inc.$3.3B
89
MBXMBX Biosciences, Inc.$3.3B
35
CLDXCelldex Therapeutics, Inc.$3.2B
31
ALMSAlumis, Inc.$3.2B
51
QUREUniQure NV$3.3B
54
IOVAIovance Biotherapeutics, Inc.$3.1B
90
IDYAIDEAYA Biosciences, Inc.$3.4B
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Arcutis Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARQT news & analysis

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 7 Aug 2026neutral

Arcutis Biotherapeutics announced the grant of 143,500 restricted stock units and options to purchase 37,000 shares of common stock to 24 newly hired employees. The inducement grants were made under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The inducement grants signal ongoing hiring and equity-based compensation for new employees, which ARQT watchers would track as part of the company's workforce and share-dilution picture.

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

A transcript of Arcutis Biotherapeutics' Q2 2026 earnings call was published on Seeking Alpha, covering the company's quarterly earnings presentation and discussion.

Why it matters — ARQT watchers can review the earnings call transcript for the company's quarterly results and management commentary.

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

Zacks Investment Research · 5 Aug 2026positive

Arcutis Biotherapeutics reported Q2 earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.13 per share in the same quarter a year ago.

Why it matters — A ARQT watcher would care because the company exceeded analyst earnings expectations and improved from a year-ago per-share loss.

Arcutis Biotherapeutics Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

Arcutis Biotherapeutics reported second-quarter 2026 net product revenue of $129.9 million, up 59% from the prior-year period and 23% sequentially. The growth was driven by continued demand for its ZORYVE topical treatments across approved dermatology indications.

Why it matters — Revenue growth for ZORYVE indicates strengthening commercial performance, which ARQT watchers would track as a key measure of the company's top-line momentum.

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 5 Aug 2026positive

Arcutis reported second quarter 2026 financial results, with ZORYVE net product revenue of $129.9 million, up 59% versus Q2 2025 and 23% versus Q1 2026, and raised its full-year 2026 net product sales guidance to $525 million–$540 million. The company also received FDA approval expanding ZORYVE cream 0.3% to children aged 2 and older with plaque psoriasis, had an sNDA accepted for ZORYVE cream 0.05% in infants with atopic dermatitis, completed enrollment of a Phase 2 vitiligo trial, and launched a virtual health platform, while maintaining positive operating cash flow.

Why it matters — The results show strong ZORYVE revenue growth, an upgraded full-year outlook, and multiple regulatory and pipeline milestones that could expand the product's addressable patient population.

FAQ

Frequently asked questions about ARQT stock

What is the ARQT stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Arcutis Biotherapeutics, Inc. have a median 12-month price target of $37, with estimates ranging from $34 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARQT stock a buy right now?

Of the 8 analysts covering Arcutis Biotherapeutics, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arcutis Biotherapeutics, Inc. 89 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARQT?

As at 15 Aug 2026, Arcutis Biotherapeutics, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will ARQT stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +41.3% from the last close, and Ticker Nerd's factor model ranks Arcutis Biotherapeutics, Inc. 89 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARQT stock forecast for 2030?

No analyst covering Arcutis Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARQT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $40 over the next 12 months.

How has ARQT stock performed over the past year?

Arcutis Biotherapeutics, Inc. returned +63.9% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arcutis Biotherapeutics, Inc. do?

Arcutis Biotherapeutics Inc. is a commercial-stage biopharmaceutical company specializing in medical dermatology and immuno-dermatology.

What is the latest news on ARQT?

The most recent item we track (GlobeNewsWire, 7 Aug 2026): "Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Arcutis Biotherapeutics announced the grant of 143,500 restricted stock units and options to purchase 37,000 shares of common stock to 24 newly hired employees. The inducement grants were made under Nasdaq Listing Rule 5635(c)(4).

Company

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Inc. is a commercial-stage biopharmaceutical company specializing in medical dermatology and immuno-dermatology. The company focuses on developing and commercializing advanced topical and systemic therapies for immune-mediated skin diseases and conditions, particularly chronic inflammatory disorders such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, scalp psoriasis, and alopecia areata. Its core franchise centers on ZORYVE, a branded formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor available in cream and foam formulations for multiple dermatologic indications. Beyond ZORYVE, Arcutis maintains a pipeline of small-molecule and biologic candidates, including topical JAK1 inhibitors and CD200R-targeting agents designed to address deeper inflammation and additional immune-mediated skin conditions. Operating within the healthcare and biotechnology sectors, Arcutis serves dermatology specialists and their patients by offering non-steroidal, targeted therapies intended to address significant unmet needs in outpatient medical dermatology. The company was incorporated in 2016 and is headquartered in Westlake Village, California.

CEO Mr. Todd Franklin Watanabe M.A. · 354 employees · United States · https://www.arcutis.com